AR 9281

Drug Profile

AR 9281

Alternative Names: AR9281

Latest Information Update: 06 Aug 2015

Price : $50

At a glance

  • Originator Arete Therapeutics
  • Class Antihypertensives; Lipids; Small molecules; Vasodilators
  • Mechanism of Action Epoxide hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hypertension; Type 2 diabetes mellitus

Most Recent Events

  • 09 Jun 2009 Pharmacokinetics, pharmacodynamics and safety data from preclinical and phase I trials presented at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA-2009) ,, ,
  • 12 Feb 2009 Phase-II clinical trials in Hypertension in USA (PO)
  • 12 Feb 2009 Phase-II clinical trials in Type-2 diabetes mellitus in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top